Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Identification of MET genomic amplification, protein expression and alternative splice isoforms in neuroblastomas.

Journal of clinical pathology - 1 Nov 2013

Yan Benedict, Lim Malcolm, Zhou Lihan, Kuick Chik Hong, Leong May Ying, Yong Kol Jia, Aung Lele, Salto-Tellez Manuel, Chang Kenneth T E

Abstract excerpt

BACKGROUND: Crizotinib, a dual anaplastic lymphoma kinase (ALK) and mesenchymal-epithelial transition (MET) tyrosine kinase inhibitor, is currently being evaluated for the treatment of neuroblastoma. Its effects are thought to be mediated mainly via its activity against ALK. Although MET genomic/protein expression status might conceivably affect crizotinib efficacy, this issue has hitherto not received attention...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anaplastic Lymphoma Kinase
Share to Crizotinib

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Epithelial-Mesenchymal Transition

Share to Neuroblastoma

Share to Proto-Oncogene Proteins c-met

Share to Pyrazoles

Share to Pyridines

Share to Tissue Array Analysis

Source

Identifiers

PMID: 23801497
DOI: 10.1136/jclinpath-2012-201375

Genes

MET
ALK

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Identification of MET genomic amplification, protein expression and alternative splice isoforms in neuroblastomas.PMID 23801497Read ↗

MET-dependent solid tumours - molecular diagnosis and targeted therapy.Semantic proximity Read ↗

MET amplification, protein expression, and mutations in pulmonary adenocarcinoma.Semantic proximity Read ↗

MET amplification, expression, and exon 14 mutations in colorectal adenocarcinoma.Semantic proximity Read ↗

MET tyrosine kinase receptor expression and amplification as prognostic biomarkers of survival in gastroesophageal adenocarcinomaSemantic proximity Read ↗

MET receptor juxtamembrane exon 14 alternative spliced variant: novel cancer genomic predictive biomarker.Semantic proximity Read ↗

<i>MET</i> amplification as a potential therapeutic target in gastric cancerSemantic proximity Read ↗

Improved diagnostics targeting c-MET in non-small cell lung cancer: expression, amplification and activation?Semantic proximity Read ↗

Understanding c-MET signalling in squamous cell carcinoma of the head & neckSemantic proximity Read ↗

Targeting MET Amplification: Opportunities and Obstacles in Therapeutic ApproachesSemantic proximity Read ↗

Gene amplification and protein overexpression of MET are common events in ovarian clear-cell adenocarcinoma: their roles in tumor progression and prognostication of the patientSemantic proximity Read ↗

MET in gastric carcinomas: comparison between protein expression and gene copy number and impact on clinical outcomeSemantic proximity Read ↗

MET genetic abnormalities unreliable for patient selection for therapeutic intervention in oropharyngeal squamous cell carcinoma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.